International Vaccine Institute and MilliporeSigma to Develop Next-Generation Purification Processes
- Company to provide expertise on clarification and purification
- Collaboration will improve manufacturing processes to deliver greater yield, allowing higher recovery and providing higher purity vaccines
Seoul, South Korea, June 30, 2016 - The International Vaccine Institute (IVI) and MilliporeSigma has entered into a research agreement to help develop more robust, scalable vaccine manufacturing processes. MilliporeSigma will provide funding and expertise to IVI in the areas of clarification and purification for vaccines that may improve the efficiency of vaccine production.
IVI is a nonprofit international organization committed to the discovery, development and delivery of safe, effective and affordable vaccines for global public health. The new collaboration between MilliporeSigma and IVI is aimed at improving the manufacturing process to deliver greater yield, allowing higher recovery and purer vaccines. Many vaccine manufacturers in the United States and Western Europe face also high manufacturing costs, and the partnership aims to addresses these challenges.
"Complex manufacturing processes along with poor yield and recovery result in vaccines that are not easily affordable by resource-challenged countries,” said Udit Batra, Member of the Executive Board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma. “Through our partnership with IVI, we will help create a more modern, scalable and robust manufacturing process, which in turn will help increase access to life-saving vaccines in developing countries."
"We expect that our collaboration with MilliporeSigma will result in important dividends to a large population of people with unmet medical needs," said Jerome Kim, MD, IVI Director General. "This partnership will help us better address the vaccine needs of low - and middle-income countries and ultimately contribute to our mission."
Initially, the project will focus on a vaccine for typhoid developed by IVI, with the goal of applying findings to the processes for pneumococcal, meningococcal, haemophilus, staphylococcus, streptococcus B and other conjugated polysaccharide vaccines.
With a rapidly expanding pipeline of conjugated polysaccharide vaccines, the global pharmaceutical industry needs next-generation processes for clarification and purification to ensure high-quality, affordable vaccines. Through this partnership with IVI, MilliporeSigma will apply its industry-leading technologies and expertise to this challenge, which in turn will help optimize other vaccine manufacturing processes.
This initiative is part of MilliporeSigma’s corporate responsibility program which focuses on expanding access to high-quality healthcare, especially in low- and middle-income countries. As part of this initiative, MilliporeSigma leverages its expertise and collaborates with strong partners to develop solutions for patients in these geographies.
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int